Heart Failure Clinical Trials

Yes. Atrial fibrillation is extremely common in heart failure patients, and most trials allow participants with this co-existing condition. Some trials even focus specifically on patients who have both heart failure and atrial fibrillation. You will need to be on appropriate anticoagulation therapy as determined by your cardiologist.

Yes, and this is a rapidly growing area. After years with few effective treatments for HFpEF, trials have recently demonstrated benefits of SGLT2 inhibitors in this population. New trials are testing additional agents and combination strategies. If you have HFpEF, there are more trial opportunities now than at any previous time.

Most trials require that you be on stable guideline-directed medical therapy (typically including a beta-blocker, an ACE inhibitor or ARB or ARNI, and often an SGLT2 inhibitor) before enrollment. The study drug is usually added to your existing regimen, not substituted for it. Some trials may adjust specific medications as part of the protocol.

Visit frequency varies but is typically every two to four weeks during the first few months and then monthly or bimonthly during the maintenance phase. Visits usually include blood work, vital signs, and symptom assessments. Some trials incorporate remote monitoring that can reduce the number of in-person visits needed.

Heart failure hospitalization is actually a key outcome that most trials track, so the study team is prepared for this scenario. You will continue to receive appropriate inpatient care, and the hospitalization will be documented as a study event. Depending on the circumstances, you may continue in the trial after discharge or be withdrawn per protocol guidelines.